Skip to main content
. 2021 Jun 9;13(12):2898. doi: 10.3390/cancers13122898

Figure 1.

Figure 1

Temporal milestones of antibody–drug conjugates currently approved for the treatment of BC. Abbreviations: HER2, human epidermal growth factor receptor 2; T-DM1, trastuzumab emtansine; T-Dxd, trastuzumab deruxtecan; EMA, European Medicines Agency; FDA, Food and Drug Administration; 1MBC, metastatic breast cancer; 2EBC, early breast cancer; 3ABC, advanced breast cancer; mTNBC, metastatic triple-negative breast cancer.